These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 29016751)

  • 1. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
    Bertero E; Prates Roma L; Ameri P; Maack C
    Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S; Alloju S; Henry RR
    Diabetes Care; 2016 Jul; 39(7):1115-22. PubMed ID: 27289124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Luconi M; Raimondi L; Di Franco A; Mannucci E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
    Xiang B; Zhao X; Zhou X
    Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
    McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
    Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of empagliflozin in patients with diabetes and heart failure.
    Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
    Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
    Wong ND; Fan W; Pak J
    Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME
    Langslet G; Zinman B; Wanner C; Hantel S; Espadero RM; Fitchett D; Johansen OE
    Diab Vasc Dis Res; 2020; 17(6):1479164120975256. PubMed ID: 33307785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.